Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

A resurgence in mergers and acquisitions dealmaking is turbocharging the market for the safest US corporate debt to its ...

DelveInsight's Hormone Replacement Therapy Market Insights report provides the current and forecast market analysis, ...

PARP Inhibitor Market is projected to expand substantially, surpassing USD 16,153.50 million by 2034 at a CAGR of 8.70%.

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA ...

AbbVie ABBV has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual ...

AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

Revance's merger with Crown Labs boosts shares, but stability concerns remain. See more about RVNC stock and why ongoing ...